HASBROUCK HEIGHTS, N.J., Jan 23, 2007 /PRNewswire via COMTEX/ -- Zymes, LLC has announced that it has affirmed that its PTS technology is Generally Recognized as Safe (GRAS) as a solubilizer for coenzyme Q10. PTS is the lead compound of Ubisol-Aqua(TM), Zymes' delivery system technology. Ubisol-Aqua(TM) provides superior platforms for solubilizing coenzyme Q10 and other water-insoluble compounds for foods, beverages, nutritional supplements and pharmaceuticals. Zymes' new water-soluble formulation of coenzyme Q10, HQO(TM), is a breakthrough for the many industries looking to supplement their products with coenzyme Q10.
Zymes' new HQO(TM) has an average particle size in water of 22 nanometers, 10 times smaller than those commercially available. It offers improved solubility, enhanced bioavailability, higher concentration and is available for licensing.
"Obtaining GRAS status for our water-soluble coenzyme Q10, HQO(TM), creates unlimited opportunities in food, beverage and nutritional markets around the world," said Benjamin D. Mamola, Co-founder and Executive Vice President of Global Business Development at Zymes. "Our new breakthrough technology finally makes it possible to deliver coenzyme Q10 in everyday products like water, soft drinks, juices and many other types of foods, beverages and nutritional supplements."
Zymes also offers its delivery system technology, Ubisol-Aqua(TM) to industry partners seeking more efficient ways of making their insoluble or lipophilic ingredients water-soluble.
"The scientific data presented within our GRAS application indicates that PTS can safely provide solubility benefits," said Randi Fain, MD, Co-founder and Executive Vice President of Clinical and Scientific Affairs. "Receiving the FDA's positive response to our GRAS application is very important to our research efforts and validates the delivery system's 14-year development process."
About Zymes: Zymes LLC is a bio-science company that combines science, technology and nature to create products that improve the quality of life. It is dedicated to contributing to the well-being of individuals by developing high-quality products that provide significant, clinically-proven health and beauty benefits to consumers. Based in Hasbrouck Heights, NJ, Zymes holds substantial intellectual property ranging from production of CoQ10 to pharmaceutical drug delivery systems. For more information, visit http://www.zymesllc.com or email [email protected]